Exciting Prospects for CytoDyn in Oncology
Dear Shareholders,
We are thrilled to share that 2025 is shaping up as a pivotal year for CytoDyn Inc. Since our recent announcement about increased survival rates in patients with metastatic Triple-Negative Breast Cancer (mTNBC) treated with leronlimab, we see ourselves on the brink of significant breakthroughs. The data, which highlights improved survival rates at the 12, 24, and 36-month marks in patients who previously struggled to find effective treatment, suggests that our innovative drug could transform the landscape of oncology.
Notably, we have observed a subgroup of patients who have reported being cancer-free following treatment – a truly inspiring development. This encouraging news is just the tip of the iceberg for our 2025 oncology narrative, and we are eager to bring you timely updates on our progress as we move forward together. While much remains to be accomplished, the outlook is indeed promising.
Commitment to Stakeholders
As the CEO of CytoDyn, I want to sincerely thank our dedicated team and the influential opinion leaders who have played integral roles in compiling this important data. Your commitment is invaluable. As firm believers in transparency, we strive to provide you, our shareholders, with honest updates regarding our milestones, regulatory engagements, and overall financial health.
Our foremost priorities for the future are to get leronlimab into the hands of patients who need it most and to generate significant value for you, our shareholders. As we continue to forge ahead, we are dedicated to providing a comprehensive view of our development journey, making sure we celebrate key milestones together.
Regulatory Progress and Financial Outlook
Our collaborative relationship with the FDA is strong, ensuring we are on a productive path forward. To enhance our progress in oncology, we are establishing an oncology advisory board, which will help us navigate the fastest and most responsible pathways available. Continuously assuring robust communication with KOLs and the FDA remains a vital component of our strategy.
From a financial standpoint, we are pleased to report that we have sufficient cash and resources to support our clinical endeavors throughout 2025. As we near key announcements, we will assess various opportunities to bolster funding at optimal moments, ensuring that our strategy aligns with the best interests of CytoDyn and its stakeholders.
Oncology Research Update
The recent survival data from our studies, particularly in solid tumors, enhances our confidence in leronlimab's potential. We've submitted our findings as an abstract to the European Society for Medical Oncology conference, highlighting our active approach to research dissemination. Our teams have initiated follow-up protocols to closely monitor patients who have shown promising outcomes, ensuring we capture comprehensive data.
Our ongoing collaborations have led to eight clinical sites now fully approved for the Phase II study focusing on patients with colorectal cancer (CRC). This network of community practices and academic institutions will enable swift recruitment and contribute to enhanced study results. As we finalize agreements, we anticipate patient screening to commence shortly.
Exploring New Frontiers in Treatment
In parallel with these developments, our healthcare teams are aggressively pursuing additional research avenues, including the use of leronlimab in treatment protocols for glioblastoma multiforme (GBM). Our preclinical study at the esteemed Albert Einstein College of Medicine is already underway, which looks promising for future studies and pilot investigations.
We are also advancing our research into treating long COVID and mild to moderate Alzheimer’s Disease (AD). We’re collaborating with leading institutions on studies that aim to elucidate leronlimab’s potential benefits in these areas, emphasizing our commitment to addressing pressing healthcare needs.
Data Publication and Community Engagement
We understand the critical importance of publicizing our clinical findings. Consequently, we are prioritizing the submission of our manuscripts to credible journals. Our research highlighting improved survival in mTNBC patients treated with leronlimab has re-focused our efforts in oncology, reflecting our ongoing commitment to contributing valuable knowledge to the scientific community.
Frequently Asked Questions
What is the latest development regarding leronlimab?
Leronlimab has shown increased survival rates in patients with mTNBC, indicating its potential as a transformative treatment in oncology.
How does CytoDyn plan to engage with the FDA moving forward?
The company is enhancing its collaboration with the FDA by forming an oncology advisory board to streamline development processes.
What are the key financial expectations for CytoDyn in 2025?
CytoDyn anticipates sufficient funding to support ongoing clinical studies and assess opportunities for additional funding to further its mission.
Which new cancer studies is CytoDyn pursuing?
CytoDyn is pursuing studies focused on colorectal cancer and glioblastoma multiforme, among others, expanding its research frontiers.
Is CytoDyn working on treatments for Alzheimer's or long COVID?
Yes, CytoDyn is developing studies to explore the effectiveness of leronlimab in treating mild to moderate Alzheimer's Disease and is seeking inclusion in long COVID treatment studies.
